FATE

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing programmed off-the-shelf cellular immunotherapies. The company utilizes human induced pluripotent stem cells (iPSCs) to create a renewable source for manufacturing engineered cell therapies. Its product pipeline includes multiplexed-engineered T cell and natural killer (NK) cell candidates designed to provide multiple therapeutic mechanisms. Fate Therapeutics aims to offer these therapies with off-the-shelf availability for patients, allowing for combination with standard-of-care treatments.